In summary, in this study we demonstrated that SOX2 overexpression occurs in a fraction of women with BRCA1 and BRCA2 mutations prior to ovarian cancer initiation and in the majority of patients with HGSOCs irrespective of tumor stage. This evidence concerns the gene SOX2 and neoplasm.